KYOWA KIRIN CO., LTD.

Amgen to host a webcast on Nov. 26, 2024, at 5 a.m. PT to discuss Phase 2 study data of MariTide and its development program, featuring Robert A. Bradway and other senior management.

Kura Oncology to participate in JMP Securities Hematology and Oncology Summit on Dec 2, 2024. The company is focused on precision medicines for cancer treatment, with ziftomenib as a key drug candidate.

Novartis acquires Kate Therapeutics for $1.1B, Barclays predicts challenging 2025 for European pharma, Trump picks surgeon Martin Makary to lead FDA, Novartis partners with Ratio Therapeutics for up to $745M, Kyowa Kirin pays Kura Oncology $330M upfront for leukemia drug rights, global measles cases rise 20% to 10.3 million, Brookfield considers €7B bid for Grifols, Bavarian Nordic's 2025 order book reaches €320M, FDA supports REGENXBIO's Duchenne muscular dystrophy gene therapy, Merck's subcutaneous Keytruda matches infused version, Syndax Pharmaceuticals secures FDA approval for Revuforj, Aclaris Therapeutics licenses 2 antibodies from Biosion for over $40M upfront, Sandoz to cut 10% of workforce in France, Incyte halts testing and discontinues drugs, Sage Therapeutics discontinues dalzanemdor, Johnson & Johnson and Merck announce job cuts in China, Samsung Biologics signs $668M contracts, FDA grants accelerated approval to Jazz Pharmaceuticals' Ziihera, Lexicon Pharmaceuticals cuts 60% of workforce, Halozyme withdraws €2B bid for Evotec, mpox epidemic overwhelms hospitals in Kinshasa.

Howard Chang, M.D., Ph.D., joins Amgen as Senior Vice President of Research and Chief Scientific Officer, effective Dec. 16, 2024, reporting to Jay Bradner, M.D.

Neutropenia treatment market to reach USD 20.8 billion by 2032, driven by cancer prevalence and chemotherapy-induced neutropenia. Rising R&D leads to new therapies like G-CSFs and oral treatments. Idiopathic neutropenia and APAC market growth are significant. Key players include Amgen, Pfizer, and Teva.

AstraZeneca's Fasenra recommended for EU approval as add-on treatment for relapsing or refractory EGPA, based on MANDARA trial results showing comparable remission rates to mepolizumab and higher OCS tapering success.

AstraZeneca's Fasenra recommended for EU approval as add-on treatment for EGPA, based on MANDARA trial results showing comparable remission rates to mepolizumab and higher OCS tapering success.

Fasenra recommended for approval in the EU by CHMP for EGPA treatment, supported by MANDARA trial showing 60% remission and 41% OCS cessation.

The study examines real-world treatment patterns for Sézary syndrome (SS) in the US from 2018 to 2020, identifying increased use of systemic treatments, particularly mogamulizumab, and variations in treatment patterns across states. The COVID-19 pandemic impacted treatment selection, with a notable drop in ECP and oral systemic therapies in Q2 2020. Despite limitations in data source and completeness, the findings highlight the complexity of therapeutic decision-making for SS.